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Objectives The aim of this study was to investigate whether multiple biomarkers contribute to improved coronary heart dis-
ease (CHD) risk prediction in post-menopausal women compared with assessment using traditional risk factors
(TRFs) only.
Background The utility of newer biomarkers remains uncertain when added to predictive models using only TRFs for CHD risk
assessment.
Methods The Women’s Health Initiative Hormone Trials enrolled 27,347 post-menopausal women ages 50 to 79 years.
Associations of TRFs and 18 biomarkers were assessed in a nested case-control study including 321 patients
with CHD and 743 controls. Four prediction equations for 5-year CHD risk were compared: 2 Framingham risk
score covariate models; a TRF model including statin treatment, hormone treatment, and cardiovascular disease
history as well as the Framingham risk score covariates; and an additional biomarker model that additionally
included the 5 significantly associated markers of the 18 tested (interleukin-6, D-dimer, coagulation factor VIII,
von Willebrand factor, and homocysteine).
Results The TRF model showed an improved C-statistic (0.729 vs. 0.699, p  0.001) and net reclassification improvement
(6.42%) compared with the Framingham risk score model. The additional biomarker model showed additional im-
provement in the C-statistic (0.751 vs. 0.729, p  0.001) and net reclassification improvement (6.45%) compared
with the TRF model. Predicted CHD risks on a continuous scale showed high agreement between the TRF and addi-
tional biomarker models (Spearman’s coefficient  0.918). Among the 18 biomarkers measured, C-reactive protein
level did not significantly improve CHD prediction either alone or in combination with other biomarkers.
Conclusions Moderate improvement in CHD risk prediction was found when an 18-biomarker panel was added to predictive
models using TRFs in post-menopausal women. (J Am Coll Cardiol 2010;55:2080–91) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.047m
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May 11, 2010:2080–91 Multimarker Prediction of CHD Riskam risk score is considered a standard and generally
cceptable approach to risk prediction (2), newer biomarkers,
hich reflect inflammation, endothelial function, fibrin forma-
ion and fibrinolysis, oxidative stress, renal function, ventricular
unction, and even myocardial cell damage, have also been
ssociated with cardiovascular risk, and their predictive values
ave been studied (3–12). A multimarker risk prediction
pproach, that is, the inclusion of several newer biomarkers
imultaneously, also has been studied with the goal of improv-
ng the accuracy and clinical utility of cardiovascular risk
rediction (13–16). Some studies have suggested that adding
everal newer biomarkers can substantially improve risk classi-
cation (15,16), but others have observed only minimal im-
rovement in the ability to classify cardiovascular risk by
dding biomarkers (13,14).
See page 2092
In current medical practice, the accurate assessment of
ardiovascular risk is considered essential for clinical deci-
ion making, because the benefits, risks, and costs of
lternative management strategies must be weighed to
hoose the best treatment for individual patients. However,
ontroversy remains both as to the utility of new markers in
ardiovascular risk assessment, especially in women, and
lso as to the best statistical methods to use in assessing the
ncremental value of new biomarkers. Blood biomarkers
ave been studied as risk factors and predictors of coronary
eart disease (CHD) in the Women’s Health Initiative
articipants (17–19). However, the predictive values of
ombining traditional risk factors (TRFs) and newer bi-
markers have not been studied thoroughly. To determine
hether new biomarkers are useful in clinical practice, their
erformance in disease prediction should be assessed by
arious indexes (20). In light of ongoing uncertainty in these
reas, we investigated whether multiple biomarkers yield a
etter assessment of cardiovascular risk in post-menopausal
omen compared with a standard risk assessment incorpo-
ating major TRFs alone.
ethods
n the present study, we used datasets from a nested
ase-control biomarker study and an 8.6% subsample study
n the WHI-HT (Women’s Health Initiative Hormone
rials). Details of the study design, data collection, inter-
ention, and outcome ascertainment in the WHI-HT,
ncluding CONSORT diagrams, have been published pre-
iously (21–23).
tudy populations. The WHI-HT enrolled 27,347 post-
enopausal women ages 50 to 79 years from 1993 to 1998 at
0 U.S. clinical centers. Post-menopausal women with prior
ysterectomies (n 10,739) were randomly assigned to receive
onjugated equine estrogen 0.625 mg/day (CEE) or placebo,
nd those with a uterus (n  16,608) were randomly assigned
o receive CEE with medroxyprogesterone acetate 2.5 mg/day dMPA) or placebo. The CEE and
EE  MPA trials were stopped
fter mean follow-up periods of
.1 and 5.6 years, respectively
24,25). Because of early adverse
ffects of hormone therapy on car-
iovascular events in the Women’s
ealth Initiative, a nested case-
ontrol study for biomarkers was
erformed. All centrally adjudi-
ated cases of CHD, stroke, and
enous thromboembolism occur-
ing during the first 4 years of
ollow-up were included in bio-
arker studies. Controls were
atched on age, randomization
ate, hysterectomy status, and
revalent cardiovascular disease
CVD) at baseline. Matching on
VD history was specific to the
ase type, but all controls for the
case types were used after ex-
luding any with incident CHD,
troke, or venous thromboembo-
ism. Eventually, the CHD biomarker study included 359
atients with CHD and 820 controls. Of the 359 partici-
ants with CHD, 11 also had strokes, 9 had venous
hromboembolism, and 1 had all 3 events. The present
tudy was restricted to 321 patients and 743 controls who
ere either white or African American and had complete
ata for blood pressure, TC, HDL-C, fasting glucose, and
urrent smoking status. Five-year incidence of CHD was
alculated for all the WHI-HT participants of white and
frican-American ethnicity. Additionally, an 8.6% sub-
ample study of the WHI-HT participants was used for the
stimation of mean risk factor levels and also for the
alidation of CHD risk prediction models. This component
f the present study included 1,261 white and 678 African-
merican women, among whom 39 incident CHD events
ere observed (Online Appendix 1).
utcome ascertainment. Clinical outcomes were identi-
ed by semiannual questionnaires and classified by centrally
rained local adjudicators following medical record review.
ll locally adjudicated cases of CHD were reviewed by
entral adjudicators. CHD included nonfatal myocardial
nfarction, CHD death, and incident silent myocardial
nfarction. Definite and probable nonfatal myocardial in-
arction required overnight hospitalization and was defined
ccording to an algorithm based on standardized criteria
sing cardiac pain, cardiac enzymes levels, and electrocar-
iographic findings and included myocardial infarction
ccurring during surgery or other procedures (26). CHD
eath was defined as death consistent with CHD as the
nderlying cause plus 1 or more of the following: hospital-
zation for myocardial infarction within 28 days before
Abbreviations
and Acronyms
ABM  additional
biomarker
CEE  conjugated equine
estrogen 0.625 mg/day
CHD  coronary heart
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
FRSN  Framingham risk
score with new coefficients
FRSO  Framingham risk
score with original
coefficients
HDL-C  high-density
lipoprotein cholesterol
MPA  medroxyprogesterone
acetate 2.5 mg/day
TC  total cholesterol
TRF  traditional risk
factoreath, previous angina or myocardial infarction, death due
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Multimarker Prediction of CHD Risk May 11, 2010:2080–91o a procedure related to CHD, or a death certificate
onsistent with the underlying cause as atherosclerotic
HD. Definite silent myocardial infarction was diagnosed
y clear changes from baseline to year 3 or year 6 electro-
ardiograms (Novacodes 5.1 and 5.2) (27).
isk factors and biomarker measurements. Demographic
nd general health characteristics were based on self-report.
urrent smokers were those who had ever smoked at least
00 cigarettes and were currently smoking. Nondrinkers
ere those who reported fewer than 12 drinks of any kind of
lcoholic beverage in their lifetimes. Medications and sup-
lement use were ascertained by a computer-driven inven-
ory system at the first screening visit. Systolic and diastolic
lood pressures were measured twice after a 5-min rest
eriod using a conventional mercury sphygmomanometer
22). Blood samples were collected and processed at baseline
nd were stored at a central biorepository at 70°C.
nalyses were run in single batches including patients and
ontrols and 10% blind duplicates within 8 years of collec-
ion. Blood analyses included fasting glucose, lipid profile,
nd a panel of 18 biomarkers: lipoprotein(a), homocysteine,
nsulin, C-reactive protein (CRP), E-selectin, interleukin-6,
atrix metalloproteinase-9, fibrin D-dimer, factor VIII,
lasminogen activator inhibitor-1 antigen, prothrombin
ragment 1.2, plasmin-antiplasmin complex, thrombin-
ctivatable fibrinolysis inhibitor, von Willebrand factor,
brinogen, hematocrit, and leukocyte and platelet counts.
asting glucose, insulin, lipid profile, lipoprotein(a), fibrin-
gen, hematocrit, and leukocyte and platelet counts were
vailable for the case-control sample and the 8.6% random
ubsample, but other biomarkers were measured only for the
ase-control sample. Detailed methods for physical assess-
ent and biomarker measurements have been described
lsewhere (18,22).
tatistical analysis. Multiple logistic regression models
ere used for the assessment of independent relationships of
isk factors and biomarkers to CHD incidence. The first
ogistic models were adjusted for age, systolic blood pres-
ure, TC, HDL-C, diabetes (fasting glucose126 mg/dl or
urrent treatment), and smoking status. The second models
ere additionally adjusted for statin use, active hormone
reatments, and history of CVD at baseline. Coefficients
ere calculated for each categorical risk factor or a 1-SD
ncrement of each continuous risk factor. Associations
etween the 18-biomarker panel and CHD risk were
ssessed with and without logarithmic transformation. The
ogarithmic scale was selected for 14 biomarkers (except for
brinogen, leukocytes, platelets, and hematocrit) because
hey had skewed distributions and showed stronger associ-
tions with CHD when log transformed.
We developed 4 prediction equations for 5-year CHD
isk. The first equation (Framingham risk score with orig-
nal coefficients [FRSO]) used coefficients from the original
ramingham risk score (1). The second equation (Framing-
am risk score with new coefficients [FRSN]) included
ystolic blood pressure, TC, and HDL-C in continuous porms and diabetes and current smoking, and the coeffi-
ients were obtained from the nested case-control study.
he third equation (TRF) included statin treatment, hor-
one treatment (CEE and CEE  MPA), and history of
VD at baseline, which were independently associated with
HD, in addition to the variables in the FRSN equation.
he fourth equation (additional biomarker [ABM]) addi-
ionally included biomarkers that were significantly associ-
ted with CHD even after adjustment for TRFs (equations
re presented in Online Appendix 2).
All blood biomarkers were additionally considered for
isk prediction by adding each single biomarker to the TRF
odel. The mean level of each risk factor was obtained from
he subsample of WHI-HT, except for biomarkers that
ere available only in the case-control study (Online Table 1).
e included hormone treatments as covariates in the
odels. Previous studies reported that CEE  MPA
reatment was associated with increased CHD risk (hazard
atio: 1.24; 95% confidence interval: 1.00 to 1.54) (25), but
ormone treatment had no significant interaction with
ther risk factors (25) or biomarkers (18) except for baseline
ow-density lipoprotein cholesterol.
The discriminatory power of each model was assessed by
he C-statistic (area under the receiver-operating character-
stic curve), and its difference between models was tested
sing a nonparametric method (28). We also calculated the
ates slope (the difference between predicted risk between
atients and controls; larger values indicate better discrim-
nation), the Brier score (the sum of squared difference
etween the observed outcome and fitted probability;
maller values indicate better fit), and the integrated dis-
rimination improvement (29,30). The increased discrim-
native value of adding TRFs and biomarkers was further
xamined with reclassification tables. This method is
ased on the difference between 2 models in the individ-
al estimated probability that a case subject will be
ategorized as a case subject. The net reclassification
mprovement (NRI) was calculated for those changes in
stimated prediction probabilities that imply a change
rom 1 category to another according to the method
escribed by Pencina et al. (30). We used risk categories
f 5%, 5% to 10%, and 10%, because the present
tudy predicted 5-year CHD risk. To assess the agree-
ents of predicted risks between different models, we
lotted scatterplots and calculated unweighted and
eighted kappa coefficients (for risk categories) and
pearman’s coefficients (for continuous risks).
As a calibration analysis, the mean predicted risk and
bserved actual risk were compared across quintiles of
redicted CHD risk in the subsample study. The signif-
cance of difference between predicted and actual risks
as tested using the Hosmer-Lemeshow chi-square test.
ecause the subsample study had relatively low incidence
nd small numbers of outcome events, we also compared
redicted and actual risks by 3 predicted risk categories
(
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May 11, 2010:2080–91 Multimarker Prediction of CHD Risk5%, 5% to 10%, and 10%). Statistical analyses were
erformed using SAS version 9.1 (SAS Institute Inc.,
ary, North Carolina) without adjustment for multiple
esting.
esults
he incidence of CHD was 3.48 per 1,000 person-years
n the entire WHI-HT and 3.67 per 1,000 person-years
n the subsample study (data are presented in Online
able 2). Baseline characteristics of the case-control
aseline Characteristics of the Patients With CHD and ControlsTable 1 Baseline Characteristics of the Patients With CHD and
Characteristic Controls (n  743), n (%)
African-American ethnicity 81 (10.9)
Hysterectomy 300 (40.4)
CVD history at baseline 103 (13.9)
Current smoker 64 (8.6)
Nondrinker 345 (46.8)
Physical inactivity 113 (17.4)
Treated diabetes mellitus 36 (4.9)
Antihypertensive drug use 195 (26.2)
Antidiabetic drug use 30 (4.0)
Statin use 65 (8.8)
Aspirin use 162 (21.8)
CEE treatment 147 (19.8)
CEE  MPA treatment 226 (30.4)
Mean  SD
Age (yrs) 66.7 6.7
BMI (kg/m2) 28.4 5.6
SBP (mm Hg) 129.6 17.4
DBP (mm Hg) 75.1 9.2
TC (mg/dl) 226.4 36.9
HDL-C (mg/dl) 54.9 14.2
LDL-C (mg/dl) 141.0 33.5
Fibrinogen (mg/dl) 308.2 84.3
Leukocytes (kcell/ml) 6.0 1.6
Platelets (kcell/ml) 248.4 56.8
Hematocrit (%) 40.5 2.7
Median (IQR)
Triglycerides (mg/dl) 132 (99–182)
Lipoprotein(a) (mg/dl) 20 (9–41)
Fasting glucose (mg/dl) 97 (90–107)
Fasting insulin (IU/ml) 7.6 (4.9–12.1)
CRP (g/ml) 2.2 (1.0–4.8)
E-selectin (ng/ml) 44 (32–57)
Interleukin-6 (pg/ml) 2.8 (2.0–4.1)
MMP-9 (ng/ml) 220 (160–305)
D-dimer (g/ml) 0.3 (0.2–0.5)
Factor VIII (%) 104.5 (73.0–137.0)
PAI-1 antigen (ng/ml) 40.0 (21.9–70.3)
Prothrombin fragment 1.2 (nmol/l) 1.3 (1.1–1.5)
PAP (nmol/l) 4.5 (3.5–5.7)
TAFI (g/ml) 5.1 (3.9–6.4)
vWF (%) 90 (66–119)
Homocysteine (mol/l) 8.1 (6.6–10.1)
MI  body mass index; CEE  conjugated equine estrogen 0.625 mg/day; CHD  coronary heart d
igh-density lipoprotein cholesterol; IQR interquartile range; LDL-C low-density lipoprotein cholesterol; MM
ctivator inhibitor; PAP  plasmin-antiplasmin complex; SBP systolic blood pressure; TAFI  thrombin-actiiomarker study are presented separately for patients and
ontrols (Table 1). The proportion of African-American
omen was not different between patients and controls.
igarette smoking, physical inactivity, CVD history,
reated diabetes, and the use of antihypertensive drugs,
ntidiabetic drugs, statins, and aspirin were more com-
on in patients, but alcohol intake was more common in
ontrols. TRFs such as systolic blood pressure, TC,
DL-C, smoking, diabetes, and CVD history as well as
tatin and active hormone treatments were independently
ssociated with CHD. However, alcohol intake, antihy-
trols
Patients (n  321), n (%) p Value for Chi-Square Test
35 (10.9) 0.9994
138 (43.0) 0.4265
85 (27.2) 0.0001
67 (20.9) 0.0001
182 (57.4) 0.0016
65 (23.6) 0.0302
57 (17.8) 0.0001
128 (39.9) 0.0001
44 (13.7) 0.0001
49 (15.3) 0.0016
101 (31.5) 0.0008
78 (24.3) 0.0979
113 (35.2) 0.1241
Mean  SD p for t Test
66.7 6.9 0.9630
29.5 5.8 0.0055
136.5 18.8 0.0001
76.6 10.5 0.0205
234.8 38.8 0.0008
50.1 13.6 0.0001
150.1 33.7 0.0001
331.1 92.4 0.0002
6.5 1.9 0.0001
247.0 59.3 0.7114
40.8 3.0 0.1461
Median (IQR) p for Wilcoxon’s Test
150 (113–217) 0.0001
22 (10–46) 0.2465
100 (91–119) 0.0001
9.3 (5.9–14.8) 0.0001
3.1 (1.5–6.5) 0.0001
46 (32–62) 0.1662
3.4 (2.5–5.2) 0.0001
235 (166–337) 0.0396
0.4 (0.2–0.7) 0.0001
119.5 (82.5–158.0) 0.0001
47.5 (26.1–77.9) 0.0553
1.4 (1.1–1.7) 0.0426
4.4 (3.5–6.0) 0.8370
5.1 (3.8–6.3) 0.3365
99 (73–139) 0.0001
8.5 (7.0–10.8) 0.0129
CRP  C-reactive protein; CVD  cardiovascular disease; DBP  diastolic blood pressure; HDL-C Con
isease;
Pmatrix metalloproteinase; MPAmedroxyprogesterone acetate 2.5mg/day; PAI plasminogen
vatable fibrinolysis inhibitor; TC total cholesterol; vWF  von Willebrand factor.
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Multimarker Prediction of CHD Risk May 11, 2010:2080–91ertensive treatment, and aspirin use were not signifi-
antly associated after adjustment for other risk factors.
mong the 18-biomarker panel, only interleukin-6,
-dimer, factor VIII, von Willebrand factor, and homo-
ysteine levels were independently associated with CHD
Table 2).
Figure 1 shows the distribution of predicted CHD risks
y 4 different models separately in cases and controls. From
he first (FRSO) through the fourth (ABM) models, the
ifference of predicted risks between cases and controls
radually increased or the discrimination improved, but
djusted ORs for CHDTable 2 Adjusted ORs for CHD
Adjusted for Age, SBP, TC, HDL-C,
Diabetes, Smoking
Variable OR (95% CI) p Value
Framingham covariates
Age (per SD) 1.04 (0.90–1.21) 0.5874
BMI (per SD) 1.10 (0.95–1.28) 0.2057
Waist (per SD) 1.17 (1.00–1.36) 0.0547
SBP (per SD) 1.46 (1.27–1.69) 0.0001
TC (per SD) 1.33 (1.15–1.52) 0.0001
HDL-C (per SD) 0.74 (0.64–0.86) 0.0001
Diabetes (yes/no) 2.32 (1.60–3.37) 0.0001
Current smoking (yes/no) 3.38 (2.25–5.09) 0.0001
Other risk factors (yes/no)
African American 0.96 (0.61–1.51) 0.8539
Physical inactivity 1.24 (0.85–1.81) 0.2594
Alcohol intake 0.72 (0.54–0.96) 0.0253
CVD at baseline 2.25 (1.58–3.20) 0.0001
Antihypertensive treatment 1.53 (1.12–2.08) 0.0072
Statin treatment 1.96 (1.28–3.00) 0.0019
Aspirin treatment 1.57 (1.15–2.15) 0.0048
CEE treatment 1.44 (1.00–2.07) 0.0480
CEE  MPA treatment 1.57 (1.13–2.16) 0.0065
Blood biomarkers (per SD)*
CRP (log) 1.16 (1.00–1.35) 0.0509
E-selectin (log) 0.96 (0.82–1.11) 0.5363
Interleukin-6 (log) 1.27 (1.10–1.47) 0.0016
MMP-9 (log) 1.06 (0.92–1.22) 0.4599
Leukocytes 1.10 (0.95–1.27) 0.2208
D-dimer (log) 1.32 (1.14–1.54) 0.0003
Factor VIII (log) 1.30 (1.12–1.52) 0.0006
PAI-1 antigen (log) 0.97 (0.83–1.13) 0.6604
Prothrombin fragment 1.2 (log) 1.05 (0.92–1.21) 0.4637
PAP (log) 1.12 (0.96–1.31) 0.1401
TAFI (log) 0.91 (0.79–1.04) 0.1608
vWF (log) 1.26 (1.09–1.46) 0.0014
Fibrinogen 1.17 (1.01–1.34) 0.0331
Platelets 0.97 (0.84–1.12) 0.6837
Hematocrit 0.94 (0.81–1.08) 0.3659
Lipoprotein(a) (log) 1.05 (0.91–1.22) 0.4785
Homocysteine (log) 1.19 (1.04–1.37) 0.0130
Fasting insulin (log) 1.17 (0.99–1.39) 0.0658Each biomarker was assessed separately.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.imultaneously, the distribution of predictive risks also
idened even within cases or controls.
Predicted CHD risks using both a continuous scale and
isk categories were compared between FRSO and FRSN,
etween FRSN and TRF, and between TRF and ABM
odels. Agreement of predicted absolute risks between
ifferent prediction models was good (Spearman’s coeffi-
ient  0.816, 0.888, and 0.918), but the agreement of risk
ategories was relatively poor (simple kappa 0.372, 0.493,
nd 0.623). The scatterplots with cutoff lines show that the
bsolute differences were minimal to moderate in most
Adjusted for Age, SBP, TC, HDL-C,
Diabetes, Smoking, Statin and
Hormone Treatments, CVD History
Adjusted for Age, SBP, TC, HDL-C,
Diabetes, Smoking, Statin and
Hormone Treatments (Excluding
Women With CVD History)
OR (95% CI) p Value OR (95% CI) p Value
1.00 (0.86–1.16) 0.9754 0.98 (0.82–1.16) 0.7887
1.07 (0.91–1.25) 0.4034 1.05 (0.88–1.26) 0.5606
1.13 (0.96–1.33) 0.1304 1.13 (0.94–1.35) 0.1915
1.49 (1.29–1.73) 0.0001 1.54 (1.30–1.83) 0.0001
1.40 (1.21–1.62) 0.0001 1.35 (1.15–1.59) 0.0003
0.73 (0.63–0.86) 0.0001 0.73 (0.61–0.87) 0.0005
2.09 (1.42–3.08) 0.0002 2.01 (1.27–3.18) 0.0027
3.39 (2.23–5.17) 0.0001 3.58 (2.24–5.71) 0.0001
0.95 (0.59–1.53) 0.8297 0.97 (0.55–1.72) 0.9119
1.27 (0.87–1.86) 0.2207 1.03 (0.66–1.62) 0.8830
0.75 (0.56–1.02) 0.0629 0.75 (0.53–1.05) 0.0879
2.03 (1.40–2.93) 0.0002
1.18 (0.84–1.65) 0.3519 0.99 (0.67–1.47) 0.9610
1.68 (1.07–2.63) 0.0238 1.29 (0.70–2.39) 0.4116
1.28 (0.91–1.80) 0.1582 1.11 (0.74–1.68) 0.6122
1.46 (1.01–2.11) 0.0452 1.55 (1.02–2.38) 0.0418
1.62 (1.16–2.26) 0.0046 1.54 (1.06–2.24) 0.0224
1.15 (0.99–1.35) 0.0756 1.18 (0.99–1.41) 0.0652
0.92 (0.79–1.08) 0.3045 0.95 (0.80–1.13) 0.5642
1.27 (1.09–1.48) 0.0025 1.25 (1.05–1.48) 0.0129
1.03 (0.89–1.19) 0.7248 1.06 (0.89–1.25) 0.5231
1.09 (0.94–1.27) 0.2441 1.09 (0.92–1.30) 0.3076
1.33 (1.14–1.56) 0.0003 1.20 (1.01–1.44) 0.0444
1.30 (1.11–1.52) 0.0014 1.17 (0.98–1.39) 0.0790
0.96 (0.82–1.13) 0.6221 1.00 (0.83–1.20) 0.9805
1.06 (0.92–1.23) 0.4095 0.95 (0.80–1.13) 0.5575
1.13 (0.97–1.33) 0.1226 1.16 (0.97–1.38) 0.1140
0.90 (0.78–1.04) 0.1612 0.89 (0.75–1.05) 0.1510
1.29 (1.11–1.49) 0.0008 1.21 (1.02–1.43) 0.0257
1.11 (0.96–1.28) 0.1643 1.13 (0.96–1.33) 0.1436
0.96 (0.82–1.11) 0.5378 1.00 (0.85–1.19) 0.9667
0.94 (0.81–1.09) 0.4410 0.97 (0.82–1.15) 0.7134
1.06 (0.91–1.23) 0.4625 1.01 (0.86–1.20) 0.8705
1.20 (1.04–1.38) 0.0117 1.18 (1.00–1.39) 0.0539
1.10 (0.92–1.31) 0.3047 1.09 (0.90–1.34) 0.3787
i
c
r
t
T
s
c
h
s
t
i
w
i
c
w
s
p
s
f

w
s
q
d
p
d
p
s
t
v
c
0
q
w
f
e
c
D
n
T
i
m
h
D
w
C
i
C
r
D
W
c
t
T
F
C
m
2085JACC Vol. 55, No. 19, 2010 Kim et al.
May 11, 2010:2080–91 Multimarker Prediction of CHD Risknstances, even if they were classified into different risk
ategories (Fig. 2).
Table 3 summarizes various indexes for discrimination,
eclassification, improved discrimination, and calibration in
he nested case-control dataset and the subsample dataset.
he ABM model could not be validated in the subsample
tudy, because ABMs were available only for the case-
ontrol study. We did not exclude women with CVD
istories at baseline, but we repeated the analysis in the
ubgroup of women without histories of CVD. Overall,
he model coefficients for risk factors were similar, but the
mprovement and reclassification by ABMs in this subgroup
ere smaller than those in all eligible participants. When we
ncluded 5 newer biomarkers that we found to be signifi-
antly associated with CHD in addition to the TRFs, NRI
as 8.07% in the case-control sample and 6.45% in the
ubgroup that was free of CVD at baseline (more data are
resented in Online Table 3). Among the CVD-free
ubgroup, 7 women who developed CHD were reclassified
rom lower or intermediate-risk groups (5-year CHD risk
10%) to the higher risk group (10%). When we included
omen with CVD histories, 20 women were reclassified
imilarly. The Hosmer-Lemeshow chi-square test by risk
uintiles and 3 risk categories did not show a significant
ifference between predicted risk and actual risk (data are
resented in Online Table 4). This indicates good calibration.
Because log CRP was associated with CHD with bor-
erline significance (p  0.077), we also assessed a CHD
rediction model that included CRP as well as the 5
ignificant biomarkers. However, the 5-biomarker model and
Figure 1 Discrimination Between Cases and Controls by Differe
Blue and red dots indicate predicted coronary heart disease (CHD) risk in controls
C-statistics were 0.679 (95% confidence interval [CI]: 0.645 to 0.714) for the Fram
0.734) for the Framingham risk score with new coefficients (FRSN) model, 0.729 (
CI: 0.718 to 0.784) for additional biomarker (ABM) model.he CRP-added 6-biomarker model were almost identical (p ialue for the difference of C-statistic  0.520, Spearman’s
oefficient for absolute risk 0.999, kappa for risk category
.967). CRP levels were also analyzed in linear, log-linear,
uadratic, and dichotomous forms, but CRP in any form
as not significantly associated with CHD after adjustment
or TRFs (data are presented in Online Table 5). We also
valuated 18 separate risk prediction models, which in-
luded a single biomarker in addition to the TRFs. Only the
-dimer-included model had significantly better discrimi-
ative power (p  0.042) than the TRF model (Table 4).
he association between D-dimer and CHD risk was
ndependent from other cardiovascular risk factors and
edication use. However, in a subgroup analysis by the
ormone treatment assignments, the association between
-dimer and CHD was marginally stronger among the women
ho received active CEE than among those who received
EE placebo (adjusted odds ratio: 1.69 vs. 1.27; p value for
nteraction  0.097), but results for the CEE  MPA and
EE  MPA placebo groups were similar (adjusted odds
atio: 1.35 vs. 1.23; p value for interaction  0.688).
iscussion
e investigated the potential usefulness of traditional
ardiovascular risk factors and 18 ABMs for CHD predic-
ion among post-menopausal women age 50 to 79 years.
he addition of CVD history and medication use to the
ramingham risk score covariates increased the model
-statistic from 0.699 to 0.729. With addition of 5 inflam-
atory and hemostatic biomarkers, the C-statistic further
rediction Models
ases, respectively, and black bars indicate medians and interquartile ranges.
m risk score with original coefficients (FRSO) model, 0.699 (95% CI: 0.665 to
I: 0.695 to 0.762) for the traditional risk factor (TRF) model, and 0.751 (95%nt P
and c
ingha
95% Cncreased to 0.751, and the corresponding NRI was 6.45%
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Multimarker Prediction of CHD Risk May 11, 2010:2080–91n women who were free of CVD at baseline. However, our
ata also suggest that improved model discrimination does
ot guarantee a better risk stratification for individual
omen, because as the number of predictors increased, the
verlap between the 2 distributions did not diminish as
xpected from the separation of the means (31).
One strategy that has been proposed to improve on the
imitations of individual biomarkers is to combine multiple
iomarkers into an integrated score or algorithm. But
he effects of multiple biomarkers in addition to the TRFs
ave been nonsignificant or minimal in many studies. In the
ramingham Heart Study, a multimarker score (combining
-type natriuretic propeptide, CRP, urinary albumin/
reatinine ratio, homocysteine, and renin) moderately im-
roved the C-statistic by 0.02 in CVD death prediction and
y 0.01 in CVD event prediction (13). In the Cardiovascu-
ar Health Study, the addition of 6 biomarkers (CRP,
brinogen, factor VIIIc, interleukin-6, lipoprotein[a], and
emoglobin) did not improve discrimination beyond estab-
ished risk factors among subjects with (difference  0.01,
 0.15) or without (difference  0.01, p  0.72) chronic
idney disease (32). In the Quebec Cardiovascular Study, an
nflammation score based on interleukin-6 and fibrinogen
evels moderately improved C-statistics (difference 0.008,
 0.03) for a CHD prediction model (33). Ridker et al.
15,34) proposed the “Reynolds risk score,” which included
RP, glycosylated hemoglobin (in women), and parental
istory of myocardial infarction in women (15) and men
34). The incremental C-statistic was 0.017 compared with
he risk predicted by Framingham covariates and 0.003
hen compared with the risk predicted by Adult Treatment
anel III covariates. Including more biomarkers, such as
polipoprotein A-I, apolipoprotein B-100, and lipopro-
ein(a), did not improve the C-statistic further (15). In a
wedish cohort study, the addition of multiple biomarkers
mproved the C-statistic for CVD prediction by 0.007 (p 
.04) and for CHD prediction by 0.009 (p  0.08) (35). In
he present study among post-menopausal women, 5 ABMs
mproved the C-statistic for CHD prediction by 0.022 (p
.001) in all women and by 0.016 (p 0.027) in a subgroup
ithout CVD history. In contrast, in an elderly male cohort
tudy (the Uppsala Longitudinal Study of Adult Men), the
-statistic for CVD death prediction increased by 0.11 (p
.001) when 4 markers (troponin I, N-terminal pro-brain
atriuretic peptide, cystatin C, and CRP) were added to
stablished markers in all participants and by 0.06 (p 
.03) in the subgroup that was free of CVD at baseline (16).
his large improvement in the Uppsala study might be
xplained at least in part by the fact that the investigators
ncluded cystatin C, troponins, and pro-brain natriuretic
eptide, which reflect existing cardiac or renal damage
16,36).
In the present study, among the 5 inflammatory markers
valuated, individually, CRP, interleukin-6, and matrix
etalloproteinase-9 levels and leukocyte count (but notFigure 2 Comparisons of Predicted 5-Year CHD
Risk Between Different Prediction Models
(A) Risks predicted by FRSO and FRSN models: simple kappa  0.372
(95% CI: 0.291 to 0.452); weighted kappa  0.419 (95% CI: 0.340 to
0.497); Spearman’s coefficient  0.816 (p  0.0001). (B) Risks predicted
by the FRSN and TRF models: simple kappa  0.493 (95% CI: 0.432 to
0.555); weighted kappa  0.579 (95% CI: 0.522 to 0.636); Spearman’s
coefficient  0.888 (p  0.0001). (C) Risks predicted by the TRF and ABM
models: simple kappa  0.623 (95% CI: 0.569 to 0.676); weighted kappa 
0.709 (95% CI: 0.664 to 0.755); Spearman’s coefficient  0.918 (p  0.0001).
Black and red dots indicate controls and cases, respectively. A logarithmic scale
is used on both axes. CHD  coronary heart disease; other abbreviations as in
Figure 1.-selectin) were positively associated with CHD. However,
o
a
a
c
C
b
(
e
W
w
S
*
h new c
2087JACC Vol. 55, No. 19, 2010 Kim et al.
May 11, 2010:2080–91 Multimarker Prediction of CHD Risknly interleukin-6 was significantly associated with CHD
fter adjustment for traditional cardiovascular risk factors
nd medication use. Model discrimination was not signifi-
antly improved by any of these 5 inflammatory markers.
RP has been most frequently studied as a potential
ummary of Model EvaluationTable 3 Summary of Model Evaluation
Variable FRSO
Discrimination in the case-control sample (n 1,064)
Yates slope 0.0086
Brier score 0.0131
C-statistic 0.6793
Discrimination in the CVD-free case-control sample (n 864)
Yates slope 0.0072
Brier score 0.0108
C-statistic 0.6774
Calibration in the 8.6% random sample (n 1,939)
Hosmer-Lemeshow chi-square for quintile risk groups 1.7409 (p 0.
Hosmer-Lemeshow chi-square for 3 risk categories 2.4016 (p 0.
Reclassification in the CVD-free case-control sample
Patients moved to higher
Patients moved to lower
Controls moved to higher
Controls moved to lower
Net reclassification improvement
Integrated discrimination improvement
Compared with FRSO model. †Compared with FRSN model. ‡Compared with TRF model.
ABM additional biomarker; CVD cardiovascular disease; FRSN Framingham risk score wit
Effects of Adding Single Biomarkers to the TRFTable 4 Effects of Adding Single Biomarkers
Associa
Biomarker
Coefficients
per 1 SD
Inflammation
CRP (log) 0.1413
E-selectin (log) 0.0763
Interleukin-6 (log) 0.2337
MMP-9 (log) 0.0265
Leukocytes 0.0898
Hemostasis
D-dimer (log) 0.2713
Factor VIII (log) 0.2533
PAI-1 antigen (log) 0.0422
Prothrombin fragment 1.2 (log) 0.0622
PAP (log) 0.1241
TAFI (log) 0.1028
vWF (log) 0.2455
Fibrinogen 0.1035
Platelets 0.0451
Hematocrit 0.0584
Others
Lipoprotein(a) (log) 0.0563
Homocysteine (log) 0.1802
Insulin (log) 0.0905
*Adjusted for SBP, TC, HDL-C, diabetes, smoking, CVD history, statin tre
model (C-statistic  0.729).
Abbreviations as in Table 1.iomarker that can improve CHD risk prediction in women
37–40) or in both sexes (8,14,41,42), but the predictive
ffects of including CRP have been inconsistent. In the
omen’s Health Study, CRP has been strongly associated
ith the risk for CVD and CHD and also with improved
FRSN TRF ABM
0.0173 0.0283 0.0442
0.0131 0.0129 0.0129
0.6993 (p 0.081*) 0.7285 (p 0.001†) 0.7510 (p 0.001‡)
0.0166 0.0183 0.0238
0.0109 0.0109 0.0111
0.7067 (p 0.029*) 0.7148 (p 0.171†) 0.7308 (p 0.027‡)
3.1228 (p 0.373) 3.3755 (p 0.337)
1.8234 (p 0.339) 2.8056 (p 0.094)
FRSO to FRSN FRSN to TRF TRF to ABM
34/228 (14.9%) 19/228 (8.3%) 26/224 (11.6%)
2/228 (0.9%) 4/228 (1.8%) 9/224 (4.0%)
23/636 (3.6%) 10/636 (1.6%) 12/614 (2.0%)
3/636 (0.5%) 9/636 (1.4%) 5/614 (0.8%)
10.89% 6.42% 6.45%
0.0094 (p 0.001) 0.0017 (p 0.015) 0.0055 (p 0.001)
oefficients; FRSO Framingham risk score with original coefficients; TRF traditional risk factor.
lhe TRF Model
ith CHD* Improvement of C-Statistic†
p
Value Difference
p
Value
0.0767 0.0032 0.2962
0.3197 0.0027 0.3355
0.0027 0.0060 0.2156
0.7245 0.0000 0.9507
0.2455 0.0003 0.8543
0.0004 0.0099 0.0423
0.0016 0.0087 0.0855
0.5981 0.0006 0.7581
0.3973 0.0009 0.6855
0.1158 0.0019 0.5204
0.1612 0.0019 0.3895
0.0010 0.0090 0.0503
0.1651 0.0023 0.3103
0.5430 0.0003 0.7400
0.4394 0.0009 0.4959
0.4625 0.0006 0.7210
0.0122 0.0049 0.2139
0.3101 0.0007 0.7354
, and hormone treatment. †Compared with traditional risk factor (TRF)628)
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Multimarker Prediction of CHD Risk May 11, 2010:2080–91isease prediction (37,38,43). A nested case-control analysis
n the Nurses’ Health Study and the Health Professional
ollow-Up Study observed that CRP was significantly
ssociated with CHD risk after adjustment for metabolic
isorders in men but not in women (40). In the British
omen’s Heart and Health Study, CRP was not signifi-
antly associated with either CHD or CVD, and it did not
mprove discrimination (39). In the Women’s Health Study,
RP levels3 mg/l were significantly associated with CVD
isk independent of metabolic abnormalities (37). However,
hat relationship was not observed in the nested case-control
tudy in the Nurses’ Health Study (40). In our present
nalysis in the WHI-HT, CRP was not significantly asso-
iated with CHD after adjustment for TRFs and did not
mprove the discriminative power of CHD prediction. A
ecent study by Shah et al. (44), which consisted of a new
nalysis of 2 prospective cohorts and a systematic review of
1 published prospective studies, found that while CRP is
onsistently associated with CHD risk, measurement of
RP provides more limited information for risk prediction
han tests of association alone might suggest. A large
ase-control study in Denmark observed that genetic vari-
nts that are strongly associated with lifelong increases of
RP levels are not associated with ischemic heart disease or
troke (45). This finding suggests that increased CRP levels
ay not be causally related with CHD.
Interleukin-6 is another frequently studied biomarker
s a potential predictor of CHD (46 – 49). Interleukin-6
s known to stimulate hepatic synthesis of acute phase
eactants such as CRP and fibrinogen and also to be
ssociated with atherosclerosis and arterial thrombosis
50 –52). In our analysis, interleukin-6 was the only
nflammatory marker that was independently associated
ith CHD, but interleukin-6 alone did not improve
HD prediction. Although interleukin-6 has been asso-
iated with CHD in some observational studies, its
ausality remains unclear (49). The British Women’s
ealth and Heart Study observed that interleukin-6 was
ot associated with CHD after adjusting for established
isk factors, and cigarette smoking and lung function
forced expiratory volume) were the main confounders
f the association of interleukin-6 and CHD (48).
-selectin, matrix metalloproteinase-9, and leukocyte
ount have also been associated with CHD risk in other
tudies, but their independent relationships and addi-
ional predictive values are uncertain (53–58).
There is increasing evidence supporting an important role
or the hemostatic system in atherosclerotic vascular disease,
nd abnormal coagulation and fibrinolysis are associated
ith risk for CHD. Various hemostatic variables have
een associated with CHD risk, even after adjustment
or TRFs, in prospective studies and meta-analyses
10,14,18,47,59 – 64), but their causality and predictive
ower are unclear. In the present study, elevated plasma
evels of D-dimer, factor VIII, von Willebrand factor, and
brinogen were significantly associated with CHD after sdjustment for TRFs, and D-dimer, factor VIII, and von
illebrand factor were significant after additional adjust-
ent for medication uses and CVD history. These
emostatic variables have been associated with CHD risk
n previous reports (10,14,47,60 – 62,64,65), and D-dimer
as been the strongest factor in some studies (47,64 – 66).
mong the 18 biomarkers analyzed in the present study,
nly D-dimer significantly increased the model discrimi-
ation (p  0.042). The association between D-dimer
nd CHD risk was independent from other risk factors,
ut the association was marginally stronger in the active
EE treatment group than in the CEE placebo group.
he potential interaction between the D-dimer concen-
ration and hormone treatment needs to be further
nvestigated.
The WHI-HT biomarker study included other biomar-
ers, such as lipoprotein(a), homocysteine, and fasting
nsulin levels, which were also associated with CHD in
eta-analyses (67–69). Homocysteine level was positively
ssociated with CHD, even after adjustment for TRFs, but
id not significantly improve CHD prediction. Observa-
ional studies (8,13,14,33,70) and hypothetical analyses
31,71,72) have shown that biomarkers’ contributions to a
isease prediction might be limited despite their significant
ssociations with the disease.
tudy limitations. Some limitations of this study need to
e considered. First, the nested case-control design has
ome disadvantages compared with a cohort study, which is
enerally preferred for the assessment of risk prediction
odel. The calibration of a risk prediction model is not
ossible in a case-control study. Thus, calibration analyses
ere performed in the random subsample study, which has a
rospective cohort design. Risk stratification results should be
nterpreted with caution in a case-control dataset, because the
isk for event or the proportion of cases is artificially fixed.
hus, the distribution of CHD risk should be calculated
eparately for cases and controls (Online Table 3), and the risk
istribution in the combined subjects are different from that in
he population (73). The coefficients for individual predictors
ere estimated by logistic regression analysis in the nested
ase-control study. Coefficients are assumed to be close be-
ween logistic regression analysis and Cox’s hazard regression
nalysis when the disease incidence is low and the risk ratios
re constant over time. We also compared the risk ratio from
he Framingham studies and odds ratio from the WHI-HT;
hey were quite similar except for smoking and diabetes, for
hich the measurements were different between the 2 studies
Online Table 6).
Second, matching on age did not allow estimation of the
oefficient for age, so we could not include age as a predictor
ariable except for the model with the original Framingham
isk score coefficients. Thus, the models in this study cannot be
irectly compared with other age-included prediction models,
or can the study findings be extrapolated to women in other
ge groups. Even without including age, the predictive models
howed acceptable discriminative power (74), presumably be-
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May 11, 2010:2080–91 Multimarker Prediction of CHD Riskause the study participants have a narrow age range (50 to 79
ears) and the coefficients were estimated independently from
ge. The age-matching might decrease the observed C-statistic
or established risk factors and inflate the increments by
BMs.
Third, we did not measure other biomarkers, such as
roponins, B-type natriuretic peptide, N-terminal pro-brain
atriuretic peptide, cystatin C, and renin, which have been
ecently reported to improve CVD prediction. Many of
hose newer biomarkers reflect existing cardiac or renal
amage (36) and are more useful in prognostic prediction
ather than in risk prediction (75,76).
Fourth, we predicted CHD risk for 5 years, which
revents comparing our results directly with those of other
tudies with 10-year risk prediction. We also used risk
ategories of 5%, 5% to 10%, and 10% for 5-year CHD
isk, instead of 10%, 10% to 19%, and 20% for
0-year CHD risk. Previous WHI-HT studies observed
hat CHD rate was constant at least until 8 years of
ollow-up (21,23).
Fifth, the validation dataset (8.6% random subsample)
as selected from the same population in which the
atients and controls were identified. Thus, the calibra-
ion results are likely optimistic indicators of what would
e found in a completely unrelated population. In addi-
ion, the random subsample study measured only a part of
iomarkers. Thus calibration analysis of ABM model was
navailable.
onclusions
n this multimarker cardiovascular risk prediction study, we
ound modest improvement in CHD risk prediction when
8 biomarkers were evaluated individually and in multi-
arker predictive models along with traditional cardiovas-
ular risk factors. Women who were reclassified with 5
BMs from lower or intermediate-risk groups to the higher
isk group and who developed CHD constituted 0.1% of
he population. We did not find CRP to add significantly to
isk prediction in the multimarker model. Our findings,
hen taken in the context of rapidly expanding research on
iomarkers and CHD risk, confirm that the majority of risk
rediction content emanates from TRFs and that the
BMs studied here, even when taken together, improve risk
rediction only moderately. The hope that existed a few
ears ago that newer biomarkers could vastly improve
ardiovascular risk prediction has not materialized at this
ime. In addition, this study confirms that newer biomarkers
re quite inconsistent from study to study in their ability to
mprove risk prediction models. This fact also reinforces the
ngoing value of the TRFs as the mainstays of CHD risk
rediction.
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